Therapy Areas: Hereditary Disorders
Enterprise Therapeutics receives up to USD7m to support clinical development of ETD002 for the treatment of CF patients
15 October 2019 -

Biopharmaceutical company Enterprise Therapeutics Ltd reported on Tuesday the receipt of up to USD7m in funding for the development of novel chloride channel modulator ETD002 from the Cystic Fibrosis Foundation's Therapeutics Development Award programme.

CF is a devastating and life-limiting genetic disease. CF patients have a significant reduction in the hydration of their airway mucus, leading to failed clearance, a high incidence of infections and rapid decline in lung function.

The company added that the milestone-related funding will support clinical development up to the end of Phase 2 for ETD002, a first-in-class TMEM16A potentiator with the potential to treat all persons with cystic fibrosis (CF), independent of their cystic fibrosis transmembrane conductance regulator (CFTR) mutation type. The ETD002 programme is targeting the calcium-activated chloride ion channel TMEM16A, resulting in an increased anion and fluid flow into the airways, thinning the mucus and increasing its clearance from the airways.

This funding will enable critical clinical research to be undertaken on the company's novel TMEM16A programme as well as highlight the potential of chloride channel modulation via alternative channels to deliver innovative and effective treatments for all CF patients.

Login
Username:

Password:


Related Headlines